First gene therapy for prevalent pathologies in neurology receives FDA IND clearance - EG 427 initiating first-in-human clinical study

June 24, 2024

• EG110A to start Phase 1b/2a clinical study in Neurogenic Detrusor Overactivity (NDO) patients 
• NDO is a severe bladder condition affecting millions of patients living with Spinal Cord Injury, Multiple Sclerosis, Parkinson’s disease and other neurological disorders
• Other severe pathologies of the bladder to be investigated following this study
• Preclinical data show EG110A’s potential for long-lasting efficacy on urinary continence and to address shortcomings of existing therapies
• Opens pathway for advancing localized gene therapy in large neurology disease populations, based on the company’s proprietary vector platform

Read the full press release in English or in French

---